Friday 16 October 2026
Export ALEC’s income statement to Excel — free account
Alector, Inc.
ALEC Healthcare Biotechnology
Alector, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $21.0 million, down 79.1% from fiscal 2024. In the quarter to June 2026, revenue fell 57.8%, EPS grew 30.0%, free cash flow grew 30.2% and total debt rose 3.27%, each against the same quarter a year earlier.
1.84
0.07
−3.66%
Follow ALEC
Alector, Inc. (ALEC) P/E ratio
Alector, Inc. has no meaningful P/E ratio: its trailing twelve-month earnings is negative. Over the past ten years it has ranged from 0.0× (October 2026) to 28.7× (August 2022) — the current reading is the lowest in ten years.
P/E ratio, daily
Embed this chart
Annual newest first
| Period | P/E ratio | Change |
|---|---|---|
| FY2025 | 0.0× | — |
| FY2024 | 0.0× | — |
| FY2023 | 0.0× | — |
| FY2022 | 0.0× | — |
| FY2021 | 0.0× | — |
| FY2020 | 0.0× | — |
| FY2019 | 0.0× | — |
| FY2018 | 0.0× | — |
| FY2017 | 0.0× | — |
| FY2016 | 0.0× | — |
Quarterly newest first
| Period | P/E ratio | Change |
|---|---|---|
| Jun 2026 | 0.0× | — |
| Mar 2026 | 0.0× | — |
| Dec 2025 | 0.0× | — |
| Sep 2025 | 0.0× | — |
| 30 more quarters | Free account |
Against its own ten years
Low 0.0×
High 28.7×
Ten-year median
0.0×
Current reading's percentile
97
P/E ratio against peers
| Company | P/E ratio |
|---|---|
| PYXS Pyxis Oncology, Inc. compare | n/m |
| ADCT ADC Therapeutics SA compare | n/m |
| LXEO Lexeo Therapeutics, Inc. compare | n/m |
| EVMN Evommune Inc. compare | n/m |
| ALEC Alector, Inc. | n/m |
| MGNX MacroGenics, Inc. compare | n/m |
| ZNTL Zentalis Pharmaceuticals, Inc. compare | n/m |
| CAMP CAMP4 Therapeutics Corporation compare | n/m |
| PLX Protalix BioTherapeutics, Inc. compare | 11.4× |
| Biotechnology industry median | 8.4× |
| Healthcare sector median | 22.8× |
| Market median | 18.1× |
What P/E ratio is
Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.
Stock Price ÷ EPS (Basic) (TTM)